Phase III COLLECT study – patient recruitment is completed
A placebo-controlled, double-blind, randomized, study to assess the efficacy and safety of Kappaproct® as an add-on to current practice in chronic active treatment refractory UC patients.
120 subjects randomized.
Czech Republic, France, Germany, Hungary, Italy, Poland and UK.
Two doses of 30 mg 4 weeks apart.
Clinical remission at week 12.
Time to / rate of colectomy and safety / tolerability during 12 months
For additional details about the study, please visit clinicaltrials.gov.